Jonathan F. Khan
264 posts

Jonathan F. Khan
@JonathanKhan7
Postdoc at Weill Cornell. Interested in cell therapy, adult + ped brain cancer, immunology, and Liverpool FC. Views are my own.
New York, USA Katılım Haziran 2017
424 Takip Edilen143 Takipçiler

Using xenograft models, we demonstate that this strategy is similarly efficacious in the context of human disease, and that combination with PD-1 targeting checkpoint blockade further augments antitumor efficacy.
jci.org/articles/view/…
English

Happy to see this story wrapped up and published! Spearheaded by my colleague and friend Janneke, we demonstrate a method to improve CAR T cell efficacy in the context of SCLC.
jci.org/articles/view/…

English
Jonathan F. Khan retweetledi
Jonathan F. Khan retweetledi

Nature research paper: TET2 guards against unchecked BATF3-induced CAR T cell expansion go.nature.com/3JVvSDM
English
Jonathan F. Khan retweetledi

Initial phase 1 results suggest that off-the-shelf #allogeneic anti-#BCMA #CAR_T cells are safe and feasible for patients with relapsed or refractory multiple #myeloma. #mmsm @MSKCancerCenter @MSK_DeptOfMed #MultipleMyeloma #NMEDClinical #Oncology
nature.com/articles/s4159…
English
Jonathan F. Khan retweetledi
Jonathan F. Khan retweetledi

In a new Review @AndrewChowMDPhD @KarloPerica @KlebanoffLab & @wolchokj discuss the immunobiology and clinical implications of T cell exhaustion for cancer immunotherapy: nature.com/articles/s4157… @MSKCancerCenter @WeillCornell




English






